May 5, 2020 / 9:13 PM / 22 days ago

Qiagen said it sees sales growth from coronavirus testing products

FRANKFURT (Reuters) - German genetic testing firm Qiagen (QIA.DE) said it expects net sales growth of at least 12% and adjusted earnings per share (EPS) of at least $0.40 for the second quarter of 2020 thanks to rising demand for products related to coronavirus testing.

Qiagen said growth in the second quarter would be driven by significant demand for various products and solutions used in coronavirus pandemic testing.

Reporting by Edward Taylor; Editing by Sandra Maler

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below